Efavirenz Pharmacokinetics during Pregnancy and Infant Washout
Antiviral Therapy · 2019-02 · 24 (2) · 95-103
DOI: 10.3851/imp3283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antiviral Therapy, online erschienen am 01.02.2018. Verfasst von Regis Kreitchmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: HIV Research Department, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Background
Limited data exist on efavirenz pharmacokinetics in HIV-positive pregnant women and neonatal washout.
Methods
HIV-infected pregnant women receiving 600 mg efavirenz once daily had intensive steady-state 24-h pharmacokinetics profiles during the second trimester (2T), third trimester (3T) and 6–12 weeks postpartum (PP). Maternal and umbilical cord blood samples were drawn at delivery and neonatal washout pharmacokinetics were determined. Therapeutic targets were the estimated 10th percentile efavirenz area under the concentration–time curve (AUC) in non-pregnant historical controls (40.0 μg•h/ml) and a trough concentration (C 24 h ) of 1 μg/ml. Data were prospectively collected within two trials: IMPAACT P1026s (United States) and PANNA (Europe).
Results
Among 42 women studied, 15, 42 and 40 had efavirenz pharmacokinetic data available in 2T, 3T and PP, respectively. Median (range) 3T age 33 (20.7–43.5) years, weight 74 (50–132) kg and gestational age 33.4 (28.4–37.9 weeks). Efavirenz AUC during the 3T (60 μg•h/ml) was similar to that reported in non-pregnant adults (58 μg•h/ml). Exposure in the 2T was lower, but within the 0.80–1.25 range. C 24 concentrations during pregnancy were lower compared to historical controls on 600 mg efavirenz, however, they were similar to the C 24 concentrations after equally potent dose of 400 mg efavirenz. Cord blood/maternal plasma concentration ratio (range) was 0.67 (0.36–0.95). Among 23 infants with washout data available, median (interquartile range) elimination half-life was 65.6 h (40.6–129). HIV RNA viral loads at delivery were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- HIV Research Department, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil.
- Departments of Pharmacy and Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
- University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences & Department of Pediatrics, University of California San Diego/Rady Children's Hospital-San Diego, San Diego, CA, USA.
- Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA.
- Department of Medical Technology, Faculty of Associated Medical Sciences, PHPT/IRD 174, Chiang Mai University, Chiang Mai, Thailand.
Förderung
- NIAID NIH HHS
Zitieren
APA
Kreitchmann, R., Schalkwijk, S., Best, B., Wang, J., Colbers, A., Stek, A., Shapiro, D., Cressey, T., Mirochnick, M., & Burger, D. (2019). Efavirenz Pharmacokinetics during Pregnancy and Infant Washout. Antiviral Therapy, 24(2), 95-103. https://doi.org/10.3851/imp3283
Vancouver
Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, et al. Efavirenz Pharmacokinetics during Pregnancy and Infant Washout. Antiviral Therapy. 2019;24(2):95-103. doi:10.3851/imp3283
BibTeX
@article{Kreitchmann2019,
author = {Kreitchmann, Regis and Schalkwijk, Stein and Best, Brookie and Wang, Jiajia and Colbers, Angela and Stek, Alice and Shapiro, David and Cressey, Tim and Mirochnick, Mark and Burger, David},
title = {Efavirenz Pharmacokinetics during Pregnancy and Infant Washout},
journal = {Antiviral Therapy},
year = {2019},
volume = {24},
number = {2},
pages = {95--103},
doi = {10.3851/imp3283}
}
EUVIMED